Skip to main content
SpringerLink
Log in

Controversies Around Epidemiology, Diagnosis and Treatment of Clostridium difficile Infection

  • Review Article
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

Clostridium difficile infection is a major public health problem. However, in recent years the epidemiology, risk factors, diagnosis, and treatment of C. difficile infection have undergone a significant change. The incidence of C. difficile has increased, not only in the healthcare sector but also in the community. Hospital-acquired infection and community-acquired disease have different risk factors, with the latter occurring in children and younger individuals without a history of antibiotic use or previous infections. From a clinician’s perspective, a quick efficient diagnosis is required for patient treatment; however, the old method of using enzyme immunoassays is insensitive and not very specific. Recent literature around diagnostic testing for C. difficile infection suggests using PCR or a two-step algorithm to improve sensitivity and specificity. More failures and recurrence with metronidazole have led to treatment algorithms suggesting its use for mild infections and switching to vancomycin if there is no clinical improvement. Alternatively, if signs and symptoms suggest severe infection, then oral vancomycin is recommended as a first-line agent. The addition of a new but costly agent, fidaxomicin, has seen some disparity between the European and North American guidelines with regard to when it should be used. Lastly, rapid developments and good results with fecal microbial transplantation have also left clinicians wondering about its place in therapy. This article reviews the literature around some of the recent controversies in the field of C. difficile infection.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Miller BA, Chen LF, Sexton DJ, Anderson DJ. Comparison of the burdens of hospital onset, healthcare facility-associated Clostridium difficile infection and of healthcare-associated infection due to methicillin-resistant Staphylococcus aureus in community hospitals. Infect Control Hosp Epidemiol. 2011;32:387–90.

    Article  PubMed  Google Scholar 

  2. Klein E, Smith DL, Laxminarayan R. Hospitalizations and deaths caused by methicillin resistant Staphylococcus aureus, United States, 1999–2005. Emerg Infect Dis. 2007;13:1840–6.

    Article  PubMed Central  PubMed  Google Scholar 

  3. Center for Disease Control and Prevention. Healthcare—associated infections progress report. 2012 Available at: http://www.cdc.gov/hai/progress-report/index.html. Accessed 27 Nov 2014.

  4. Ghantoji SS, Sail K, Lairson DR, et al. Economic healthcare costs Clostridium difficile infection: a systematic review. J Hosp Infect. 2010;74:309–18.

    Article  CAS  PubMed  Google Scholar 

  5. Hall IC, O’Toole E. Intestinal flora in newborn infants with a description of a new pathogenic anaerobe, Bacillus difficile. Am J Dis Child. 1935;49:390–402.

    Article  Google Scholar 

  6. Bartlett JG, Chang TW, Gurwith M, Gorbach SL, Onderdonk AB. Antibiotic-associated pseudomembranous colitis due to toxin producing clostridia. N Engl J Med. 1978;298:531–4.

    Article  CAS  PubMed  Google Scholar 

  7. Tedesco FJ, Barton RW, Alpers DH. Clindamycin-associated colitis. A prospective study. Ann Intern Med. 1974;81:429–33.

    Article  CAS  PubMed  Google Scholar 

  8. Steiner, C., Barrett, M. and Terrel, L. HCUP projections: Clostridium difficile hospitalizations 2011–2012. 2012. HCUP projections report # 2012–01. US Agency for Health-care Research and Quality. Available at: http://www.hcup-us.ahrq.gov/reports/projections/2012–01.pdf. Accessed 27 Nov 2014.

  9. Canadian nosocomial infection surveillance program. Public Health Agency of Canada. Available at: http://www.phac-aspc.gc.ca/nois-sinp/projects/cdad-eng.php. Accessed 20 Apr 2015.

  10. Jones AM, Kuijper EJ, Wilcox MH. Clostridium difficile: A European perspective. J Infect. 2013;66(2):115–28.

    Article  CAS  PubMed  Google Scholar 

  11. Bauer MP, Notermans DW, van Benthem BH, Brazier JS, Wilcox MH, Rupnik M, et al. Clostridium difficile infection in Europe: a hospital-based survey. Lancet. 2011;377(9759):63–73.

    Article  PubMed  Google Scholar 

  12. Indra A, Huhulescu S, Fiedler A, Kernbichler S, Blaschitz M, Allerberger F. Outbreak of Clostridium difficile 027 infection in Vienna, Austria 2008–2009. Euro Surveill 2009;14 (17) (2009).

  13. Asensio A, Vaque-Rafart J, Calbo-Torrecillas F, Gestal-Otero JJ, Lopez-Fernandez F, Trilla-Garcia A, et al. Increasing rates in Clostridium difficile infection (CDI) among hospitalised patients, Spain 1999–2007. Euro Surveill 2008;13 (31).

  14. Jen MH, Saxena S, Bottle A, Pollok R, Holmes A, Aylin P. Assessment of administrative data for evaluating the shifting acquisition of Clostridium difficile infection in England. J Hosp Infect. 2012;80:229–37.

    Article  CAS  PubMed  Google Scholar 

  15. Miniño AM, Xu JQ, Kochanek KD. Deaths: preliminary data for 2008. Natl Vital Stat Rep 2010; 59. Hyattsville, MD: National Center for Health Statistics. Available at: http://www.cdc.gov/nchs/data/nvsr/nvsr59/nvsr59_02.pdf. Accessed 10 Sept 2011.

  16. Loo VG, Poirier L, Miller MA, et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile—associated diarrhea with high morbidity and mortality. New Engl J Med. 2005;353:2442–9.

    Article  CAS  PubMed  Google Scholar 

  17. Hubert B, Loo VG, Bourgault AM, et al. A portrait of the geographic dissemination of the Clostridium difficile North American pulsed-field type 1 strain and the epidemiology of C. difficile—associated disease in Quebec. Clin Infect Dis. 2007;44:238–44.

    Article  CAS  PubMed  Google Scholar 

  18. Pepin J, Valiquette L, Alary ME, et al. Clostridium difficile—associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity. CMAJ. 2004;171:466–72.

    Article  PubMed Central  PubMed  Google Scholar 

  19. Kuijper EJ, Coignard B, Tull P; ESCMID Study Group for Clostridium difficile; EU Member States, European Centre for Disease Prevention and Control. Emergence of Clostridium difficile-associated disease in North America and Europe. Clin Microbiol Infect. 2006;12(Suppl 6):2–18.

  20. McDonald LC, Owings M, Jernigan DB. Clostridium difficile infection in patients discharged from US short-stay hospitals, 1996–2003. Emerg Infect Dis. 2006;12:409–15.

    Article  PubMed Central  PubMed  Google Scholar 

  21. McDonald LC, Killgore GE, Thompson A, et al. An epidemic, toxin gene-variant strain of Clostridium difficile. New Engl J Med. 2005;353:2433–41.

    Article  CAS  PubMed  Google Scholar 

  22. MacCannell DR, Louie TJ, Gregson DB, et al. Molecular analysis of Clostridium difficile PCR ribotype 027 isolates from Eastern and Western Canada. J Clin Microbiol. 2006;44:2147–52.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  23. Bacci S, et al. Binary toxin and death after Clostridium difficile infection. Emerg Infect Dis. 2011;17:976–82.

    Article  PubMed Central  PubMed  Google Scholar 

  24. Wilcox MH, Shetty N, Fawley WN, Shemko M, Coen P, Birtles A, et al. Changing epidemiology of Clostridium difficile infection following the introduction of a national ribotyping based surveillance scheme in England. Clin Infect Dis. 2012;55:1056–63.

    Article  CAS  PubMed  Google Scholar 

  25. Kuijper EJ, et al. Emergence of Clostridium difficile—associated disease in North America and Europe. Clin Microbiol Infect. 2006;12(Suppl 6):2–18.

    Article  CAS  PubMed  Google Scholar 

  26. Kelly CP, LaMont JT. Clostridium difficile infection. Annu Rev Med. 1998;49:375–90.

    Article  CAS  PubMed  Google Scholar 

  27. Brown E, Talbot GH, Axelrod P, Provencher M, Hoegg C. Risk factors for Clostridium difficile toxin—associated diarrhea. Infect Control Hosp Epidemiol. 1990;11:283–90.

    Article  CAS  PubMed  Google Scholar 

  28. Hensgens MP, Goorhuis A, Dekkers OM, Kuijper EJ. Time interval of increased risk for Clostridium difficile infection after exposure to antibiotics. J Antimicrob Chemother. 2012;67:742–8.

    Article  CAS  PubMed  Google Scholar 

  29. Gerding DN, Olson MM, Peterson LR, Teasley LR, Gebhard RL, Schwartz ML, Lee JT Jr. Clostridium difficile—associated diarrhea and colitis in adults. Arch Intern Med. 1986;146:95–100.

    Article  CAS  PubMed  Google Scholar 

  30. Riley TV. Antibiotic-associated diarrhoea. A costly problem. Pharmacoeconomics. 1996;10:1–3.

    Article  CAS  PubMed  Google Scholar 

  31. Thomas C, Stevenson M, Williamson DJ, Riley TV. Clostridium difficile—associated diarrhea: epidemiological data from Western Australia associated with a modified antibiotic policy. Clin Infect Dis. 2002;35:1457–62.

    Article  PubMed  Google Scholar 

  32. Pepin J, Saheb N, Coulombe MA, et al. Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile—associated diarrhea: a cohort study during an epidemic in Quebec. Clin Infect Dis. 2005;41:1254–60.

    Article  CAS  PubMed  Google Scholar 

  33. Raza S, Baig MA, Russell H, Gourdet Y, Berger BJ. Clostridium difficile infection following chemotherapy. Recent Pat Antiinfect Drug Discov. 2010;5:1–9.

    Article  CAS  PubMed  Google Scholar 

  34. Janarthanan S, Ditah I, Adler DG, Ehrinpreis MN. Clostridium difficile—associated diarrhea and proton pump inhibitor therapy: a meta-analysis. Am J Gastroenterol. 2012;107:1001–10.

    Article  CAS  PubMed  Google Scholar 

  35. Leonard J, Marshall JK, Moayyedi P. Systematic review of the risk of enteric infection in patients taking acid suppression. Am J Gastroenterol. 2007;102:2047–56.

    Article  PubMed  Google Scholar 

  36. Dial S, et al. Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile—associated disease. JAMA. 2005;294:2989–95.

    Article  CAS  PubMed  Google Scholar 

  37. Center for Disease Control and Prevention. Surveillance for community—associated Clostridium difficile—Connecticut, 2006. MMWR. 2008;57:340–3.

    Google Scholar 

  38. Wheeler JG, et al. Study of infectious intestinal disease in England: rates in the community, presenting to general practice, and reported to national surveillance. BMJ. 1999;318(7190):1046–50.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  39. Hirshon JM, et al. Clostridium difficile infection in outpatients, Maryland and Connecticut, USA, 2002-2007. Emerg Infect Dis. 2011;17(10):1946–9.

    Article  PubMed Central  PubMed  Google Scholar 

  40. Wilcox MH. Overcoming barriers to effective recognition and diagnosis of Clostridium difficile infection. Clin Microbiol Infect. 2012;18(Suppl 6):13–20.

    Article  PubMed  Google Scholar 

  41. Cohen SH, Gerding DN, Johnson S, Kelly CP, Loo VG, McDonald LC, Pepin J, Wilcox MH. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect Control Hosp Epidemiol. 2010;31:431–55.

    Article  PubMed  Google Scholar 

  42. Ramaswamy R, Grover H, Corpuz M, Daniels P, Pitchumoni CS. Prognostic criteria in Clostridium difficile colitis. Am J Gastroenterol. 1996;91:460–4.

    CAS  PubMed  Google Scholar 

  43. Dansinger ML, Johnson S, Jansen PC, Opstad NL, Bettin KM, Gerding DN. Protein-losing enteropathy is associated with Clostridium difficile diarrhea but not with asymptomatic colonization: a prospective, case–control study. Clin Infect Dis. 1996;22:932–7.

    Article  CAS  PubMed  Google Scholar 

  44. Bartlett JG. Leukocytosis and Clostridium difficile—associated diarrhea. Am J Gastroenterol. 2000;95:3023–4.

    Article  CAS  PubMed  Google Scholar 

  45. Price AB, Davies DR. Pseudomembranous colitis. J Clin Pathol. 1977;30:1–12.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  46. Kyne L, Merry C, O’Connell B, et al. Factors associated with prolonged symptoms and severe disease due to Clostridium difficile. Age Ageing. 1999;28:107–13.

    Article  CAS  PubMed  Google Scholar 

  47. Surawicz CM, Brandt LJ, Binion DG, Ananthakrishnan AN, Curry SR, Gilligan PH, McFarland LV, Mellow M, Zuckerbraun BS. Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. Am J Gastroenterol. 2013;108:478–98.

    Article  CAS  PubMed  Google Scholar 

  48. Oldfield EC IV, et al. Diagnosis and treatment of CDI. World J Gastrointest Pharmacol Ther. 2014;5:1–26.

    Article  Google Scholar 

  49. Musher DM, Stager C. Diagnosis of Clostridium difficile infection. Clin Infect Dis. 2012;54:1675–6.

    Article  PubMed  Google Scholar 

  50. Curry S. Clostridium difficile. Clin Lab Med. 2010;30:329–42.

    Article  PubMed  Google Scholar 

  51. American Society for Microbiology. A practical guidance document for the laboratory detection of toxigenic Clostridium difficile, September 21, 2010. Available from: http://www.alere.com/content/dam/alere/docs/guidelines/2010_ASM_guidelines_dated_9.21.10.pdf. Accessed 11 Nov 2014.

  52. Planche T, Aghaizu A, Holliman R, Riley P, Poloniecki J, Breathnach A, Krishna S. Diagnosis of Clostridium difficile infection by toxin detection kits: a systematic review. Lancet Infect Dis. 2008;8:777–84.

    Article  PubMed  Google Scholar 

  53. Fong KS, Fatica C, Hall G, Procop G, Schindler S, Gordon SM, Fraser TG. Impact of PCR testing for Clostridium difficile on incident rates and potential on public reporting: is the playing field level? Infect Control Hosp Epidemiol. 2011;32:932–3.

    Article  PubMed  Google Scholar 

  54. Planche T, Aghaizu A, Holliman R, et al. Diagnosis of Clostridium difficile infection by toxin detection kits: a systematic review. Lancet Infect Dis. 2008;8:777–84.

    Article  PubMed  Google Scholar 

  55. Alfa MJ, Kabani A, Lyerly D. et al. Characterization of a toxin A-negative, toxin B-positive strain of Clostridium difficile responsible for a nosocomial outbreak of C. difficile-associated diarrhea. J Clin Microbiol. 2000;38:2706–14.

  56. Lyerly DM, Barroso LA, Wilkins TD. Identification of the latex test-reactive protein of Clostridium difficile as glutamate dehydrogenase. J Clin Microbiol. 1991;29:2639–42.

    CAS  PubMed Central  PubMed  Google Scholar 

  57. Lyerly DM, Ball DW, Toth J, et al. Characterization of cross-reactive proteins detected by Culturette brand rapid latex test for Clostridium difficile. J Clin Microbiol. 1988;26:397–400.

    CAS  PubMed Central  PubMed  Google Scholar 

  58. Shetty N, Wren MW, Coen PG. The role of glutamate dehydrogenase for the detection of Clostridium difficile in faecal samples: a meta-analysis. J Hosp Infect. 2011;77:1–6.

    Article  CAS  PubMed  Google Scholar 

  59. Gilligan PH. Is a two-step glutamate dehyrogenase antigen-cytotoxicity neutralization assay algorithm superior to the premier toxin A and B enzyme immunoassay for laboratory detection of Clostridium difficile? J Clin Microbiol. 2008;46:1523–5.

    Article  PubMed Central  PubMed  Google Scholar 

  60. Goldenberg SD, Cliff PR, Smith S, et al. Two-step glutamate dehydrogenase antigen real-time polymerase chain reaction assay for detection of toxigenic Clostridium difficile. J Hosp Infect. 2010;74:48–54.

    Article  CAS  PubMed  Google Scholar 

  61. Larson AM, Fung AM, Fang FC. Evaluation of tcdB real-time PCR in a three-step diagnostic algorithm for detection of toxigenic Clostridium difficile. J Clin Microbiol. 2010;48:124–30.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  62. Kvach EJ, Ferguson D, Riska PF, Landry ML. Comparison of BD GeneOhm Cdiff real-time PCR assay with a two-step algorithm and a toxin A/B enzyme-linked immunosorbent assay for diagnosis of toxigenic Clostridium difficile infection. J Clin Microbiol. 2010;48:109–14.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  63. Tenover FC, Novak-Weekley S, Woods CW, Peterson LR, Davis T, Schreckenberger P, Fang FC, Dascal A, Gerding DN, Nomura JH, Goering RV, Akerlund T, Weissfeld AS, Baron EJ, Wong E, Marlowe EM, Whitmore J, Persing DH. Impact of strain type on detection of toxigenic Clostridium difficile: comparison of molecular diagnostic and enzyme immunoassay approaches. J Clin Microbiol. 2010;48:3719–24.

    Article  PubMed Central  PubMed  Google Scholar 

  64. Sethi AK, Al-Nassir WN, Nerandzic MM, Bobulsky GS, Donskey CJ. Persistence of skin contamination and environmental shedding of Clostridium difficile during and after treatment of C. difficile infection. Infect Control Hosp Epidemiol. 2010;31:21–7.

    Article  PubMed  Google Scholar 

  65. Bamber AI, Fitzsimmons K, Cunniffe JG, Beasor CC, Mackintosh CA, Hobbs G. Diagnosis of Clostridium difficile-associated disease: examination of multiple algorithms using toxin EIA, glutamate dehydrogenase EIA and loop-mediated isothermal amplification. Br J Biomed Sci. 2012;69:112–8.

    CAS  PubMed  Google Scholar 

  66. Wilcox MH, Planche T, Fang FC, Gilligan P. What is the current role of algorithmic approaches for diagnosis of Clostridium difficile infection? J Clin Microbiol. 2010;48:4347–53.

    Article  PubMed Central  PubMed  Google Scholar 

  67. Nelson RL, Kelsey P, Leeman H, et al. Antibiotic treatment for Clostridium difficile-associated diarrhea in adults. Cochrane Database Syst Rev. 2011;(9):CD004610. doi:10.1002/14651858.CD004610.pub4.

  68. Drekonja DM, Butler M, MacDonald R, et al. Comparative effectiveness of C. difficile treatments: a systematic review. Ann Intern Med. 2011;155(12):839–47.

    Article  PubMed  Google Scholar 

  69. Keighley MR, Burdon DW, Arabi Y, Williams JA, Thompson H, Youngs D, et al. Randomised controlled trial of vancomycin for pseudomembranous colitis and postoperative diarrhoea. Br Med J. 1978;2:1667–9.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  70. Wullt M, Odenholt I. A double-blind randomized controlled trial of fusidic acid and metronidazole for treatment of an initial episode of Clostridium difficile-associated diarrhoea. J Antimicrob Chemother. 2004;54(1):211–6.

    Article  CAS  PubMed  Google Scholar 

  71. Wenisch C, Parschalk B, Hasenhündl M, Hirschl AM, Graninger W. Comparison of vancomycin, teicoplanin, metronidazole, and fusidic acid for the treatment of Clostridium difficile-associated diarrhea. Clin Infect Dis. 1996;22:813–8.

    Article  CAS  PubMed  Google Scholar 

  72. Musher DM, Logan N, Bressler AM, Johnson DP, Rossignol JF. Nitazoxanide versus vancomycin in Clostridium difficile infection: a randomized, double-blind study. Clin Infect Dis. 2009;48:e41–6.

    Article  CAS  PubMed  Google Scholar 

  73. Boero M, Berti E, Morgando A, Verme G. Treatment of pseudomembranous colitis: a randomized controlled trial with rifaximin vs vancomycin [Terapia della colite da Clostridium difficile: risultati di uno studio randomizzato aperto rifaximina vs. vancomicina]. Microbiol Med. 1990;5:74–7.

    Google Scholar 

  74. Musher DM, Logan N, Hamill RJ, Dupont HL, Lentnek A, Gupta A, et al. Nitazoxanide for the treatment of Clostridium difficile colitis. Clin Infect Dis. 2006;43:421–7.

    Article  CAS  PubMed  Google Scholar 

  75. Lagrottereria D, Holmes S, Smieja M, Smaill F, Lee C. Prospective, randomized inpatient study of oral metronidazole versus oral metronidazole and rifampin for treatment of primary episode of Clostridium difficile associated diarrhea. Clin Infect Dis. 2006;43:547–52.

    Article  Google Scholar 

  76. Young GP, Ward PB, Bayley N, Gordon D, Higgins G, Trapani JA, et al. Antibiotic-associated colitis due to Clostridium difficile: double-blind comparison of vancomycin with bacitracin. Gastroenterology. 1985;89:1038–45.

    CAS  PubMed  Google Scholar 

  77. Dudley MN, McLaughlin JC, Carrington G, Frick J, Nightingale CH, Quintiliani R. Oral bacitracin vs vancomycin therapy for Clostridium difficile induced diarrhea. A randomized double-blind trial. Arch Intern Med. 1986;146:1101–4.

    Article  CAS  PubMed  Google Scholar 

  78. de Lalla F, Nicolin R, Rinaldi E, Scarpellini P, Rigoli R, Manfrin V, et al. Prospective study of oral teicoplanin versus oral vancomycin for therapy of pseudomembranous colitis and Clostridium difficile-associated diarrhea. Antimicrob Agents Chemother. 1992;36:2192–6.

    Article  PubMed Central  PubMed  Google Scholar 

  79. Teasley DG, Gerding DN, Olson MM, Peterson LR, Gebhard RL, Schwartz MJ, Lee JT. Prospective randomised trial of metronidazole versus vancomycin for Clostridium-difficile associated diarrhoea and colitis. Lancet. 1983;2:1043–6.

    Article  CAS  PubMed  Google Scholar 

  80. Pepin J, Alary ME, Valiquette L, et al. Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada. Clin Infect Dis. 2005;40:1591–7.

    Article  CAS  PubMed  Google Scholar 

  81. Musher DM, Aslam S, Logan N, et al. Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole. Clin Infect Dis. 2005;40:1586–90.

    Article  CAS  PubMed  Google Scholar 

  82. Olsson-Liljequist B, Nord CE. In vitro susceptibility of anaerobic bacteria to nitroimidazoles. Scand J Infect Dis Suppl. 1981;26:42–5.

    CAS  PubMed  Google Scholar 

  83. Pelaez T, Alcala L, Alonso R, Rodriguez-Creixems M, Garcia-Lechuz JM, Bouza E. Reassessment of Clostridium difficile susceptibility to metronidazole and vancomycin. Antimicrob Agents Chemother. 2002;46:1647–50.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  84. Bolton RP, Culshaw MA. Faecal metronidazole concentrations during oral and intravenous therapy for antibiotic associated colitis due to Clostridium difficile. Gut. 1986;27:1169–72.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  85. Keighley MR, Burdon DW, Arabi Y, et al. Randomised controlled trial of vancomycin for pseudomembranous colitis and postoperative diarrhoea. BMJ. 1978;2:1667–9.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  86. Baird DR. Comparison of two oral formulations of vancomycin for treatment of diarrhoea associated with Clostridium difficile. J Antimicrob Chemother. 1989;23:167–9.

    Article  CAS  PubMed  Google Scholar 

  87. Apisarnthanarak A, Razavi B, Mundy LM. Adjunctive intracolonic vancomycin for severe Clostridium difficile colitis: case series and review of the literature. Clin Infect Dis. 2002;35:690–6.

    Article  PubMed  Google Scholar 

  88. Centers for Disease Control and Prevention. Recommendations for preventing the spread of vancomycin resistance: recommendations of the Hospital Infection Control Practices Advisory Committee (HICPAC). Am J Infect Control. 1995;23:87–94.

    Article  Google Scholar 

  89. Zar FA, Bakkanagari SR, Moorthi KM, Davis MB. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis. 2007;45:302–7.

    Article  CAS  PubMed  Google Scholar 

  90. Optimer Pharmaceuticals Inc. Munsbach, Luxembourg. Product Monograph. Dificid (fidaxomicin). [Internet]. 2013. Available from: http://www.optimerpharma.ca/Dificid%20PM_14Jan2013.pdf. Accessed 17 Nov 2014.

  91. Gerber M, Ackermann G. OPT-80, a macrocyclic antimicrobial agent for the treatment of Clostridium difficile infections: a review. Exp Opin Invest Drugs. 2008;17:547–53.

    Article  CAS  Google Scholar 

  92. Louie T, Emery J, Krulicki W, Byrne B, Mah M. OPT-80 eliminates Clostridium difficile and is sparing of bacteroides species during treatment of C. difficile infection. Antimicrob Agents Chemother. 2009;53:261–3.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  93. Tannock G, Munro K, Taylor C, Lawley B, Young W, Byrne B, et al. A new macrocyclic antibiotic, fidaxomicin (OPT-80), causes less alteration to the bowel microbiota of Clostridium difficile-infected patients than does vancomycin. Microbiology. 2010;156:3354–9.

    Article  CAS  PubMed  Google Scholar 

  94. Louie TJ, Miller MA, Mullane KM, Weiss K, Lentnek A, Golan Y, et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med. 2011;364:422–31.

    Article  CAS  PubMed  Google Scholar 

  95. Cornely OA, Crook DW, Esposito R, Poirier A, Somero MS, Weiss K, et al. Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial. Lancet Infect Dis. 2012;12:281–9.

    Article  CAS  PubMed  Google Scholar 

  96. Crook DW, Walker AS, Kean Y, et al. Fidaxomicin versus vancomycin for Clostridium difficile infection: meta-analysis of pivotal randomized controlled trials. Clin Infect Disease. 2012;55:S93–104.

    Article  CAS  Google Scholar 

  97. Barbut F, Richard A, Hamadi K, et al. Epidemiology of recurrences or reinfections of Clostridium difficile—associated diarrhea. J Clin Microbiol. 2000;38:2386–8.

    CAS  PubMed Central  PubMed  Google Scholar 

  98. Johnson S, Adelmann A, Clabots CR, et al. Recurrences of Clostridium difficile diarrhea not caused by the original infecting organism. J Infect Dis. 1989;159:340–3.

    Article  CAS  PubMed  Google Scholar 

  99. Bartlett JG. Antibiotic-associated diarrhea. Clin Infect Dis. 1992;15:573–81.

    Article  CAS  PubMed  Google Scholar 

  100. Musher DM, Aslam S, Logan N, et al. Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole. Clin Infect Dis. 2005;40:1586–90.

    Article  CAS  PubMed  Google Scholar 

  101. Kyne L, Warny M, Qamar A, et al. Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea. Lancet. 2001;357:189–193.

  102. Nair S, Yadav D, Corpuz M, et al. Clostridium difficile colitis: factors influencing treatment failure and relapse—a prospective evaluation. Am J Gastroenterol. 1998;93:1873–6.

    CAS  PubMed  Google Scholar 

  103. Vardakas KZ, Polyzos KA, Patouni K, et al. Treatment failure and recurrence of Clostridium difficile infection following treatment with vancomycin or metronidazole: a systematic review of the evidence. Int J Antmicrob Agents. 2012;40:1–8.

    Article  CAS  Google Scholar 

  104. Pepin J, Routhier S, Gagnon S, et al. Management and outcomes of a first recurrence of Clostridium difficile—associated disease in Quebec, Canada. Clin Infect Dis. 2006;42:758–64.

    Article  PubMed  Google Scholar 

  105. Kapoor K, Chandra M, Nag D, et al. Evaluation of metronidazole toxicity: a prospective study. Int J Clin Pharmacol Res. 1999;19:83–8.

    CAS  PubMed  Google Scholar 

  106. Fugitani S, George WL, Murthy AR. Comparison of clinical severity score indices for Clostridium difficile infection. Infect Control Hosp Epidemiol 2011;32(3):220–8.

    Article  Google Scholar 

  107. Debast SB, Bauer MP, Kuijper EJ, European Society of Clinical Microbiology and Infectious Diseases. Update of the treatment guidance document for Clostridium difficile infection. Clin Microbiol Infect. 2014;20:1–26.

    Article  CAS  PubMed  Google Scholar 

  108. Eiseman B, Silen W, Bascon GS, Kauvar AJ. Fecal enema as an adjunct in the treatment of pseudomembranous enterolitis. Surgery. 1958;44:854–9.

    CAS  PubMed  Google Scholar 

  109. Schwan A, Sjölin S, Trottestam U, Aronsson B. Relapsing Clostridium difficile enterocolitis cured by rectal infusion of homologous faecaes. Lancet. 1983;2:845.

    Article  CAS  PubMed  Google Scholar 

  110. Kassam Z, Lee CH, Yuan Y, Hunt RH. Fecal microbiota transplantation for Clostridium difficile infection: systematic review and meta-analysis. Am J Gastroenterol. 2013;108:500–8.

    Article  PubMed  Google Scholar 

  111. Cammarota G, Ianiro G, Gasbarrini A. Fecal microbiota transplantation for the treatment of Clostridium difficile infection: a systematic review. J Clin Gastroenterol. 2014;48(8):693–702.

    Article  PubMed  Google Scholar 

  112. Chang JY, Antonopoulos DA, Kalra A, et al. Decreased diversity of the fecal microbiome in recurrent Clostiridum difficile—associated diarrhea. J Infect Dis. 2008;197(3):435–8.

    Article  PubMed  Google Scholar 

  113. Song Y, Garg S, Girotra M, et al. Microbiota dynamics in patients treated with fecal microbiota transplantation for recurrent Clostridium difficile infection. PLoS One. 2013;8(11):e81330.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  114. Dutta SK, Girotra M, Garg S, et al. Efficacy of combined jejunal and colonic fecal microbiota transplantation for recurrent Clostridium difficile infection. Clin Gastroenterol Hepatol. 2014;12:1572–6.

    Article  PubMed  Google Scholar 

  115. Duncan SH. Lactate-utilizing bacteria, isolated from human feces, that produce butyrate as a major fermentation product. Appl Environ Microbiol. 2004;70(10):5810–7.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  116. Van Nood e, Vrieze A, Nieuwdorp M, et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med. 2013;368:407–15.

  117. Youngster I, Russell GH, Pindar C, Zin-Baran T, Sauk J, Hohmann EL. Oral, capsulized, frozen fecal microbiota transplantation for relapsing Clostridium difficile infection. JAMA. 2014;312(17):1772–8.

    Article  CAS  PubMed  Google Scholar 

  118. Lee CH, Belanger JE, Kassam Z, et al. The outcome and long-term follow-up of 94 patients with recurrent and refractory Clostridium difficile infection using single to multiple fecal microbiota transplantation via retention enema. Eur J Clin Microbiol Infect Dis. 2014;33:1425–8.

    Article  CAS  PubMed  Google Scholar 

  119. Quera R, Espinoza R, Estay C, Rivera D. Bacteremia as an adverse event of fecal microbiota transplantation in a patient with Crohn’s disease and recurrent Clostridium difficile infection [Letter to the editor]. J Crohns Colitis. 2014;8(3):252–3.

    Article  PubMed  Google Scholar 

  120. Brandt LJ, Aroniadis OC, Mellow M, et al. Long-term follow-up of colonoscopic fecal microbiota transplant for recurrent Clostridium difficile infection. Am J Gastroenterol. 2012;107:1079–98.

    Article  PubMed  Google Scholar 

  121. Leon LD, Watson JB, Kelly CR. Transient flare of ulcerative colitis after fecal microbiota transplantation for recurrent Clostridium difficile infection. Clin Gastroenterol Hepatol. 2013;11(8):1036–8.

    Article  PubMed  Google Scholar 

  122. Hamilton MJ, Weingarden AR, Sadowsky MJ, Khoruts A. Standardized frozen preparation for transplantation of fecal microbiota for recurrent Clostridium difficile infection. Am J Gastroenterol. 2012;107:761–7.

    Article  PubMed  Google Scholar 

  123. Bakken JS, Borody T, Brandt LJ, et al. Treating Clostridium difficile infection with fecal microbiota transplantation. Clin Gastroenterol Hepatol. 2011;9:1044–9.

    Article  PubMed Central  PubMed  Google Scholar 

  124. Bakken JS. Fecal bacteriotherapy for recurrent Clostridium difficile infection. Anaerobe. 2009;15:285–9.

    Article  PubMed  Google Scholar 

  125. Postigo R, Kim JH. Colonoscopic versus nasogastric fecal transplantation for the treatment of Clostridium difficile infection: a review and pooled analysis. Infection. 2012;40:643–8.

    Article  CAS  PubMed  Google Scholar 

  126. Kassam Z, Lee CH, Hunt RH. Review of the emerging treatment of Clostridium difficile infection with fecal microbiota transplantation and insights into future challenges. Clin Lab Med. 2014;34:787–98.

    Article  PubMed  Google Scholar 

  127. Friedman-Moraco RJ, Mehta AK, Lyon GM, Kraft CS. Fecal microbiota transplantation for refractory Clostridium difficile colitis in solid organ transplant recipients. Am J Transplant. 2014;14:477–80.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  128. Moayyedi P, Marshall JK, Yuan Y, et al. Canadian Association of Gastroenterology position statement: fecal microbiota transplant therapy. Can J Gastroenterol. 2014;28:1–3.

    Google Scholar 

  129. Zipursky JS, Sidorsky TI, Freedman CA, Sidorsky MN, Kirkland KB. Patient attitudes toward the use of fecal microbiota transplantation in the treatment of recurrent Clostridium difficile infection. Clin Infect Dis. 2012;55:1652–8.

    Article  PubMed  Google Scholar 

  130. Konijeti GG, Sauk J, Shrime MG, Gupta M, Ananthakrishnan AN. Cost-effectiveness of competing strategies for management of recurrent Clostridium difficile infection: a decision analysis. Clin Infect Dis. 2014;58:1507–14.

    Article  PubMed Central  PubMed  Google Scholar 

  131. FDA. Guidance for industry: enforcement policy regarding investigational new drug requirements for use of fecal microbiota for transplantation to treat Clostridium difficile infection not responsive to standard therapies. 2013. Available from URL: http://www.fda.gov/biologicsbloodvaccines/guidancecomplianceregulatoryinformation/guidances/vaccines/ucm361379.htm. Accessed 19 Dec 2014.

  132. Food and Agriculture Organization of the UN and WHO. Report of a joint FAO/WHO working group on drafting guidelines for the evaluation of probiotics in food. Geneva (Switzerland): World Health Organization; 2002. Available at: http://www.who.int/entity/foodsafety/fs_management/en/probiotic_guidelines.pdf. Accessed 18 Apr 2015.

  133. Parkes GC, Sanderson JD, Whelan K. The mechanisms and efficacy of probiotics in the prevention of Clostridium difficile-associated diarrhea. Lancet Infect Dis. 2009;9:237–44.

    Article  PubMed  Google Scholar 

  134. Allen SJ. The potential of probiotics to prevent Clostridium difficile infection. Infect Dis Clin N Am. 2015;29:135–44.

    Article  Google Scholar 

  135. Evans CT, Johnson S. Prevention of Clostridium difficile infection with probiotics. Clin Infect Dis. 2015;60(suppl 2):S122–8.

    Article  PubMed  Google Scholar 

  136. Chapman CM, Gibson GR, Rowland I. Health benefits of probiotics: are mixtures more effective than single strains? Eur J Nutr. 2011;50:1–17.

    Article  CAS  PubMed  Google Scholar 

  137. Johnston BC, Ma SS, Goldenberg JZ, et al. Probiotics for the prevention of Clostridium-difficile-associated diarrhea: a systematic review and meta-analysis. Ann Intern Med. 2012;157:878–88.

    Article  PubMed  Google Scholar 

  138. Goldenberg JZ, Ma SS, Saxton JD, et al. Probiotics for the prevention of Clostridium difficile-associated diarrhea in adults and children. Cochrane Database Syst Rev 2013:CD006095. doi:10.1002/14651858.CD006095.pub3.

  139. Hempel S, Newberry SJ, Maher AR, et al. Probiotics for the prevention and treatment of antibiotic-associated diarrhea: a systematic review and meta-analysis. JAMA. 2012;307(18):1959–69.

    Article  CAS  PubMed  Google Scholar 

  140. Pattani R, Palda VA, Hwang SW, Shah PS. Probiotics for the prevention of antibiotic-associated diarrhea and Clostridium difficile infection among hospitalized patients: systematic review and meta-analysis. Open Med. 2013;7:e56–67.

    PubMed Central  PubMed  Google Scholar 

  141. Allen SJ, Wareham K, Wang D, et al. Lactobacilli and bifidobacteria in the prevention of antibiotic-associated diarrhea and Clostridium difficile diarrhea in older inpatients (PLACIDE): a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2013;382:1249–57.

    Article  PubMed  Google Scholar 

  142. Issa I, Moucari R. Probiotics for antibiotic-associated diarrhea: do we have a verdict? World J Gastroenterol. 2014;20(47):1788–95.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University of British Columbia, 2405 Wesbrook Mall, Vancouver, BC, V6T 1Z3, Canada

    Fawziah Marra & Karen Ng

  2. BC Children’s and Women’s Hospital, Vancouver, BC, Canada

    Karen Ng

Authors
  1. Fawziah Marra
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Karen Ng
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Fawziah Marra.

Ethics declarations

Funding

This project received no funding.

Conflict of interest

The authors of this paper have no conflicts of interest with any of companies involved in the diagnosis or treatment of Clostridium difficile.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Marra, F., Ng, K. Controversies Around Epidemiology, Diagnosis and Treatment of Clostridium difficile Infection. Drugs 75, 1095–1118 (2015). https://doi.org/10.1007/s40265-015-0422-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40265-015-0422-x

Keywords

Search

Navigation